Real-World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis
- PDF / 910,600 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 25 Downloads / 164 Views
SHORT COMMUNICATION
Real‑World Effectiveness and Safety of Apremilast in Older Patients with Psoriasis Céline Phan1,14 · Nathalie Beneton2,14 · Juliette Delaunay3,14 · Ziad Reguiai4,14 · Claire Boulard5,14 · Anne‑Claire Fougerousse6,14 · Elisa Cinotti7,14 · Marco Romanelli8,14 · Laure Mery‑Bossard9,14 · Domitille Thomas‑Beaulieu9,14 · Josiane Parier10,14 · François Maccari10,14 · Guillaume Chaby11,14 · Marie Bastien12,14 · Edouard Begon13,14 · Mahtab Samimi4,14 · Francesca Prignano14,15 · Alain Beauchet14,16 · Emmanuel Mahé1,14 · for the GEM Resopso
© Springer Nature Switzerland AG 2020
Abstract Introduction Apremilast is a drug recently developed for psoriasis. Few data are available on its use in the elderly. We evaluated the tolerance and effectiveness of apremilast used in daily practice for psoriasis treatment in older patients. Methods We performed a multicenter, retrospective study involving patients aged ≥ 65 years who had received apremilast as a psoriasis treatment. Demographic data and details regarding psoriasis and adverse events (AEs) were collected from patient medical records. Results 135 patients were included (mean age: 73.5 years). Treatment was stopped in 74 patients (54.8%) for AEs (n = 43, 56.6%), primary failures (n = 18, 23.4%), and relapses (n = 7, 9.2%). When patients were stratified by age at treatment initiation, the main cause of discontinuation in patients ≥ 75 years was AEs, whereas in patients aged 65–74 years it was primary failures (28.3%). Sixty-one patients reported AEs, mainly digestive (n = 49). Regarding effectiveness, 45.2% of patients reached PGA 0/1 between 3 and 6 months after treatment initiation. One-year apremilast continuation rates were better in the 65–74 and 75–84 years subgroups than in the > 85 years subgroup (p = 0.01). Conclusion Apremilast seems to be an effective and safe therapeutic option for psoriasis in the elderly. The main AEs reported by patients did not seem to differ from those reported previously in younger populations. However, AEs were more frequent in patients > 75 years old leading to more frequent discontinuation of apremilast compared with younger patients, suggesting a higher level of vigilance is needed in the elderly.
Key Points Little information is available on the use of apremilast in older patients with psoriasis.
The members of the GEM Resopso are detailed in the Acknowledgments section.
Apremilast seems to be an effective and safe therapeutic option with, however, more frequent AEs in patients > 75 years leading to more frequent discontinuation of treatment.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s40266-020-00781-y) contains supplementary material, which is available to authorized users. * Céline Phan celine.phan@ch‑argenteuil.fr Extended author information available on the last page of the article Vol.:(0123456789)
1 Introduction Psoriasis is a chronic inflammatory disease, mainly involving the skin and joints. Genetic factors play an important role in the et
Data Loading...
